World News

'Misleading' Heart Drug Ad; JenaValve Deal Thwarted; SGLT2 Inhibitor to Prevent HF

https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c

'Misleading' Heart Drug Ad; JenaValve Deal Thwarted; SGLT2 Inhibitor to Prevent HF (MedPage Today) — A TV commercial for bempedoic acid/ezetimibe (Nexlizet) was deemed “false or misleading” by the FDA due to claims the drug is the only nonstatin to lower bad cholesterol and reduce the risk of heart attacks.
After a 6-day court…

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button